Genetic testing; buyer beware


Don’t Count on 23andMe to Detect Most Cancer Risks, Study Warns 
https://www.nytimes.com/2019/04/16/health/23andme-brca-gene-testing.html

23andMe, (a commercial non–referral genetic testing company), now has more than 10 million customers. 23andMe’s outmoded test focuses on BRCA1 and BRCA2 gene mutations involved in suppressing growth of abnormal cells. 

18 percent of ovarian cancer patients in a recent survey* carried genetic variants, 3/4 of which would not have been detected by 23andMe.

Mary-Claire King, a professor at the University of Washington says,  “The F.D.A. should not have permitted this out-of-date approach to be used for medical purposes”. “Misleading, falsely reassuring results from incomplete testing can cost women’s lives.”
*https://acmg.expoplanner.com/index.cfm?do=expomap.sess&event_id=13&session_id=10414



Comments

Post a Comment

Popular posts from this blog

An impossible dream?

Image
Reducing ovarian cancer mortality through screening: an impossible dream? https://tinyurl.com/4524jh8f The history of screening tests for ovarian cancer is not good. Two huge trials; the UKCTOCS with  more than 200,000 recruits over 20 years and the PLCO trial with more than 3 million pathology samples  sho wed no benefit in terms of survival from ovarian cancer. This article addresses the stages of ovarian cancer using  an alternative approach called the clinical continuum,  which divides cancer into 3 phases ,  no disease, pre-clinical  (detectable disease) , and  clinical (overt cancer). Obviously for a screening test to be effective ,   cancer needs to be detected before the clinical  phase. However, ovarian cancer is unlike other cancer in that the precursor occurs in the fallopian tube and the re is an argument to say that ,  by the time ovarian cancer has occurred ,  it is always advanced and metastatic .   T his time in...
Read more

It’s not just your genotype

Image
Exploring causal relationships between brain imaging-derived phenotypes and ovarian cancer risk: a bidirectional Mendelian randomization https://tinyurl.com/yhfkpwyb One of the perplexing aspects of ovarian cancer is why there is individual variation between those who do have cancer and those who don’t . It would be expected that women with high risk due to genetic mutation such as BR CA2 would all eventually succumb to breast or ovarian cancer. However, many (about 2 0%) , do not. This study suggests that brain structure and function may be part of the reason this is so. Magnetic Resonance Imaging (MRI) is able in a non-invasive way to identify different brain shapes and anatomy . Using data from the UK Biobank study it has bee n possible to identify 12 distinct varieties of brain anatomy which have an influence on ovarian cancer. Further investigation suggested distinct areas of brain cortex variation, with the right medial cortex being protective , and the right pre-cen...
Read more

Sugar doesn’t feed cancer

Image
Revisiting the Warburg-Based “Sugar Feeds Cancer” Hypothesis: A Critical Appraisal of Epidemiological, Experimental and Mechanistic Evidence https://tinyurl.com/3v2tysdt Many clinical care professionals receive queries from cancer patients about whether they should modify their diet to red u ce consumed sugar. This concern is based on a misunde r standing of some basic medical research known as the Warbur g effect. Research from 1956 show ed that cancer cells alter their metaboli sm to enable increased glucose uptake and increase energy production. A misunderstanding of this effect has led to incorrect dietary advice to cancer patients suggesting sugar restriction may be benefi cial. As a result, malnutrition , which is already a s i gnificant cause of morbidity for cancer patients , can be exacerbated . No hard evidence that low sugar diets alter survival exists. Some anecdotal reports suggest a slight correlation with risk. This study is a n appraisal of all credible re...
Read more